SECTOR UPDATE



Another quarter of uncertainty

The performance of Chemical companies during Q2FY26 shall be directly and indirectly impacted by tariffs imposed by the US. Q2FY26 being a seasonally soft quarter shall incrementally weigh on growth prospects. A deflationary environment in major commodities continues to persist, further pressurising spreads. Hence, we forecast volume growth and margins shall be under pressure for PCBL, Deepak Nitrite, Fine Organics and PI Industries.

On the positive side, fluorine companies are likely to outperform relatively—SRF Limited and Gujarat Fluorochemicals are anticipated to benefit from strong pricing in refrigerant gases as well as fluoropolymers.

Mixed bag performance likely

In Q2FY26, Indian specialty and chemical companies are likely to post a mixed set of numbers. We reckon PI Industries, Deepak Nitrite, Fine Organics and PCBL shall report a weak performance due to product-specific headwinds (pyroxasulfone, weak phenol acetone spreads and lower carbon black realisations) and muted demand from the US. Others such as SRF, Gujarat Fluorochemicals, Jubilant Ingrevia, Aarti Industries and Galaxy Surfactants are likely to report steady to strong YoY growth. The quarter broadly reflects better performances led by fluorochemicals, refrigerants and certain specialty chemicals while agrochemicals and intermediates, phenolics, additives and commodity-linked segments continue to struggle.

Outperformers and underperformers

Among all companies, SRF and Gujarat Fluorochemicals are likely to deliver the strongest performances with robust growth in chemicals, refrigerants and fluoropolymers, supported by margin expansion. On the other hand, PI Industries and Deepak Nitrite are likely to disappoint the most with PI hit by a steep drop in Pyroxasulfone sales and weather-related disruptions and Deepak Nitrite suffering from weak phenol-acetone spreads and margin erosion in its phenolics business.

Macro variables largely beneficial for sector

Crude prices have been steady on a QoQ basis, but have dipped sharply by 14% YoY. However, we notice that commodity prices have moved in line with crude prices, which may stymie margin expansion on a YoY basis. INR depreciation would continue to benefit net exporters—the rupee has depreciated by 6% YoY/3.5% QoQ. At the same time, companies with higher FCBs in borrowings can report a forex loss.

Exhibit 1: Q2FY26 estimates and commentary

Company	Particulars	Q2FY26E	Q2FY25A	Y-o-Y %	Q1FY26A	Q-o-Q %	Comments					
Aarti Industries	Revenue (INR mn)	18,485	18,485 16,280 13.5 16		16,750	10.4	Aarti Industries' Q1FY26 was affected by deferred shipments of MMA, which are likely to be recouped in Q2FY26. We anticipate both MMA and PDCB to have been					
	EBITDA (INR mn)	2,624	1,960 587	33.9	2,110 430	24.4	hurt in Q2FY26 due to exposure to the US and the uncertabuying behaviour of customers would settle only in Q3FY26. Thus, sales are likely to be up 13.5% YoY to					
	PAT (INR mn)	692		17.9		61	INR18.4bn while EBITDA is likely to surge 34% YoY to INR2.62bn. PAT is likely to grow 17.9% YoY to INR692mn.					
Deepak Nitrite	Revenue (INR mn)	19,971	20,320	-1.7	18,899	5.7	Deepak Nitrite is likely to report good growth in the advanced intermediates business to INR7.15bn, up 18% YoY. In contrast, weak phenol acetone spreads are likely to					
	EBITDA (INR mn)	2,071	2,975	-30.4	1,896	9.2	keep Phenolics business under pressure with sales/EBIT of INR13bn, down 10% YoY/48% YoY. Realisations and spreads continue to be under pressure, which may hurt					
	PAT (INR mn)	1,257	1,942	-35.3	1,123	11.9	sales/EBITDA/PAT leading to a decline of 1.7%/30.4%/35.3% YoY.					
Fine Organics	Revenue (INR mn)	6,002	5,958	0.7	5,884	2	Fine Organics's performance in Q2FY26 is likely to be steady QoQ. We expect some improvement in volumes QoQ. Our apprehension for Q2FY26 on volume impact is on the back					
	EBITDA (INR mn)	1,351	1,506	-10.3	1,236	9.3	of Fine Organics's higher exposure to the US (15–18% sales comes from US). Hence, we expect it to report flattish YoY					
	PAT (INR mn)	1,061	1,179	-10	1,120	-5.3	top line and decline in EBITDA of 10.3% YoY to INR1.35bn. PAT is expected to dip 10% YoY to INR1.06bn.					
Galaxy Surfactant	Revenue (INR mn)	12,115	10,630	14	12,779	-5.2	Galaxy Surfactants's top-line growth of 14% is likely to be largely led by pricing. Volume growth for the quarter is					
	EBITDA (INR mn)	1,356	1,277	6.2	1,239	9.5	likely to be 3–5%. We reckon EBITDA/ton at INR19,121/ton, marginally up 1.9% YoY. EBITDA/PAT growth is likely to be					
	PAT (INR mn)	923	847	9	795	16.1	6.2% YoY/9.0% YoY.					
Gujarat Fluorochemicals	Revenue (INR mn)	13,543	11,880	14	12,810	5.7	Sustained growth in fluoropolymers will aid Gujarat Fluorochemicals to report a solid Q2FY26. We also expect very little impact from R-32's loss of production during the quarter due to the gas leak incident. We expect top-line					
	EBITDA (INR mn)	3,554	2,950	20.5	3,440	3.3	growth of 14% YoY to INR13.5bn. We forecast fluoropolymers business to deliver 25% YoY growth to INR8.75bn while bulk chemicals and fluorochemicals					
	PAT (INR mn)	1,758	1,210	45.3	1,840	-4.5	business are likely to deliver low single-digit growth. We forecast EBITDA/PAT growth of 20.5% YoY/45.3% YoY to INR3.55bn/INR1.75bn.					
Jubilant Ingrevia	Revenue (INR mn)	10,894	10,452	4.2	10,380	5	Jubilant Ingrevia's steady quarterly performance shall be driven by sequentially flattish specialty chemicals business, and a volume-led pickup in acetyls business. We expect					
	EBITDA (INR mn)	1,372	1,246	10.1	1,421	-3.5	sales growth of 4.2% YoY to INR10.8bn. EBITDA growth of 10.1% YoY to INR1.37bn should be driven by sustained profitability from specialty chemicals. We expect a gradual, albeit slow pickup in CDMO revenue Q2FY26 onwards while					
	PAT (INR mn)	678	630	7.7	751	-9.7	gradually improving trends for acetic anhydride demand and some contribution from food grade Niacinamide to lead to a robust quarterly performance.					

Source: Company, Nuvama Research

Exhibit 2: Q2FY26 estimates and commentary

Company	Particulars	Q2FY26E	Q2FY25A	Y-o-Y %	Q1FY26A	Q-o-Q %	Comments			
PI Industries	Revenue (INR mn)	17,890	22,210 6,282	-19.5 -27.8	19,005	-5.9	PI Industries' Q2YF26 is likely to be soft. We expect sales/EBITDA/PAT to decrease 19.5%/27.8%/34.7% YoY to INR17.8bn/4.5bn/3.3bn. We anticipate CSM growth to slow-down significantly due to lower sales from Pyroxasulfone.			
	EBITDA (INR mn)	4,537			5,191	-12.6	While the impact of sales from Biologicals continues, even domestic formulation business is likely to be compromised due to excessive flooding in the western and northern parts of India. We expect the pharma business to replicate the Q1FY26 performance.			
	PAT (INR mn)	3,320	5,082	-34.7	4,000	-17				
SRF	Revenue (INR mn)	37,111	33,341 5,380	11.3 54.5	38,186	-2.8	SRF Limited is likely to deliver another robust quarter. We expect sales/EBITDA growth of 11.3% YoY to INR37.1bn/54.5% YoY to INR 8.31bn. The chemicals business is likely to			
	EBITDA (INR mn)	8,310			8,298	0.1	be a growth driver, within which we expect 20%-plus growth from refrigerant gases (which is largely price led growth). Specialty Chemicals is likely to grow in high single-			
	PAT (INR mn)	5,360	2,014	166.1	4,323	24	digit in Q2FY26. However, we expect specialty chemicals be a bigger growth driver in H2FY26 as we expect contribution of new Als to start.			
PCBL	Revenue (INR mn)	21,100	21,632 3,635	-2.5 -8.6	21,141	-0.2	We reckon a soft quarter for PCBL with volumes and prices			
	EBITDA (INR mn)	3,322			3,191	4.1	both muted in Q2FY26 for the CB business. We expect sales/EBITDA/PAT decline of 2.5%/8.6%/25.6% YoY to			
	PAT (INR mn)	919	1,235	-25.6	941	-2.3	INR21.1bn/INR3.3bn/INR919mn.			

Source: Company, Nuvama Research

Exhibit 3: Valuation snapshot

	Rating	CMP (INR)	Target Price	Upside / downside	Target Multiple	Mca p (USD mn)	Mca p (INR bn)	EPS			P/E			EV/EBITDA			RoE (%)	
								FY25E	FY26E	FY27E	FY25E	FY25E	FY27E	FY25E	FY26E	FY27E	FY26E	FY27E
<u>Specialty</u> <u>Chemicals</u>																		
Aarti Industries	Reduce	381	358	-6%	25xFY28E EPS	3,307	130.4	9.1	11.4	13.2	41.7	33.5	28.9	17.3	15.4	13.4	7.1	7.7
Deepak Nitrite	Hold	1,852	1,848	0%	30xQ1FY28E EPS	3,050	238.6	51.1	53.8	61.0	36.2	34.5	30.3	23.4	22.2	19.8	12.9	13.0
Fine Organics	Buy	4,635	5,791	25%	40xQ1FY28E EPS	1,993	134.2	133.9	132.0	139.1	34.6	35.1	33.3	25.9	25.6	23.3	16.3	14.9
Galaxy Surfactants	Buy	2,247	3,069	37%	27xQ1FY28E EPS	1,297	75.3	86.0	99.8	113.4	26.1	22.5	19.8	16.3	13.5	11.8	14.0	14.2
Gujarat Fluorochemicals Limited	Buy	3,702	5,298	43%	40xQ1FY28E	4087	384.1	49.7	79.9	125.7	74.5	46.4	29.4	38.6	25.7	17.8	13.3	18.0
Jubilant Ingrevia	Buy	667	868	30%	SOTP Based	992	100.4	15.9	20.1	26.9	42.0	33.2	24.8	21.7	18.4	14.2	10.5	12.9
PI Industries	Hold	3,617	3,655	1%	35xQ1FY28E EPS	5,265	518.4	109.2	95.4	102.8	33.1	37.9	35.2	24.1	26.2	23.5	13.5	13.0
SRF	Buy	2,919	3,622	24%	SOTP Based	8,137	817.4	42.2	68.1	95.8	69.2	42.9	30.5	33.4	24.3	18.4	14.9	18.1
PCBL Limited	Hold	384	394	3%	12xQ1FY28E EBITDA		136.9	11.5	14.6	17.3	33.4	26.3	22.2	14.6	13.5	12.1	14.3	15.6
Mean											43.4	34.7	28.3	23.9	20.5	17.1	13.0	14.2
Median											36.2	34.5	29.4	23.4	22.2	17.8	13.5	14.2

Source: Company, Nuvama Research

All price charts cannot be included given the large of number of companies in our coverage. Specific charts may be available upon request.

DISCLAIMER

Nuvama Wealth Management Limited (defined as "NWML" or "Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No L67110MH1993PLC344634) having its Registered office situated at 801-804, Wing A, Building No. 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, Investment Adviser, Research Analyst and other related activities. Name of Compliance/Grievance officer: Mr. Atul Bapna, E-mail address: compliance-officer.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com

This Report has been prepared by NWML in the capacity of a Research Analyst having SEBI Registration No.INH000011316 and Enlistment no. 5723 with BSE and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWML and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWML reserves the right to make modifications and alterations to this statement as may be required from time to time. NWML or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWML is committed to providing independent and transparent recommendation to its clients. Neither NWML nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future p

NWML shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWML to present the data. In no event shall NWML be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWML through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWML and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWML may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWML (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWML or provide any assurance of returns to investors and clients.

NWML or its associates may have received compensation from the subject company in the past 12 months. NWML or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWML or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWML's associates may have financial interest in the subject company. NWML and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. NWML, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWML has financial interest in the subject companies: No

NWML's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWML has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWML on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers

Disclaimer for U.S. Persons

This research report is a product of NWML, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by NWML only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, NWML has entered into an agreement with a U.S. registered broker-dealer, Nuvama Financial Services Inc. (formerly Edelweiss Financial Services Inc.) ("NFSI"). Transactions in securities discussed in this research report should be effected through NFSI.

Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Disclaimer for Canadian Persons

This research report is a product of NWML, which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by NWML only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

NWML is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) NWML is not registered in the Province of Ontario to trade in securities; (ii) NWML's head office or principal place of business is located in India; (iii) all or substantially all of NWML's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against NWML because of the above; and (v) the name and address of the NWML's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario MSJ 273 Canada.

Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Nuvama Investment Advisors Private Limited (NIAPL) (Previously Edelweiss Investment Advisors Private Limited ("EIAPL")) (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to NIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact NIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Disclaimer for Hong Kong persons

This report is distributed in Hong Kong by Nuvama Investment Advisors (Hong Kong) Private Limited (NIAHK) (Previously Edelweiss Securities (Hong Kong) Private Limited (ESHK)), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance "SFO". This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.

Abneesh Roy Head of Research Committee Abneesh.Roy@nuvama.com